Non-small cell lung cancer (multiple settings); Small cell lung cancer (extensive-stage, first-line with carboplatin and etoposide); Hepatocellular carcinoma (with bevacizumab); Melanoma (with cobimetinib and vemurafenib); Alveolar soft part sarcoma
NSCLC/SCLC/HCC: 1200 mg IV q3w or 840 mg IV q2w or 1680 mg IV q4w
Infusion time: First infusion over 60 min; subsequent over 30 min if tolerated
Injection: 60 mg/mL solution in 14 mL (840 mg) and 20 mL (1200 mg) single-dose vials
Refer to the complete prescribing information for contraindications. Tecentriq prescribing should account for patient-specific factors including hypersensitivity to the active ingredient or any excipients.
Fatigue (44%), decreased appetite (26%), nausea (24%), cough (21%), dyspnea (18%), rash (16%), constipation (14%), diarrhea (14%)
Consult the complete prescribing information for a comprehensive list of adverse reactions and their frequencies.
Consult the complete prescribing information for drug interactions, including effects on CYP enzymes, transporters, and concomitant medications that may require dose adjustments or monitoring.
Consult the full prescribing information for pregnancy-related considerations.
Refer to prescribing information for lactation guidance.
Pediatric safety and efficacy information is detailed in the full label.
Dose modifications for organ impairment are specified in the complete prescribing information.
Atezolizumab is a humanized IgG1 monoclonal antibody that binds to PD-L1 and blocks its interactions with both PD-1 and B7.1 receptors. This releases PD-L1/PD-1-mediated inhibition of the anti-tumor immune response, including reactivation of the anti-tumor immune response without inducing antibody-dependent cellular cytotoxicity.
Half-life: 27 days. Clearance: 0.20 L/day. Vd: 6.9 L. Steady-state by 6-9 weeks. Linear PK at doses 1-20 mg/kg. Not affected by age, body weight, gender, albumin, tumor burden, or mild-moderate renal/hepatic impairment.
Clinical efficacy and safety data supporting the approval are available in the full prescribing information and from the clinical trials listed below.
Tecentriq has FDA-approved indications across the following cancer types covered on PipelineEvidence: